Citation Information :
Kuri HR, Sharma A, Meshram T, Kothari N, Goyal S, Paliwal B, Mohammed S, Bhatia P. Effects of Early Use of Methylene Blue and Vasopressin on Noradrenaline Dose in Septic Shock: A Randomized Controlled Trial. Indian J Crit Care Med 2025; 29 (2):108-112.
Background: This study aimed to assess the influence of early administration of methylene blue (MB) and vasopressin on the dose of noradrenaline required to manage septic shock.
Materials and methods: This study was a parallel, randomized, controlled trial including 74 adult patients with septic shock admitted to the intensive care unit (ICU). Once the noradrenaline requirement exceeded 0.2 µg/kg/min, patients were randomly allotted to group M and group V. Group M received an intravenous 1 mg/kg bolus of MB over 30 minutes, then an infusion of 0.5 mg/kg over 6 hours. Group V received intravenous vasopressin at a rate of 0.04 units/min for 6 hours. The primary outcome of this research was the dose of noradrenaline required to reach the target mean arterial pressure (MAP) of ≥ 65 mm Hg at 6, 12, and 24 hours. Secondary outcomes included changes in lactate levels, urine output, and sequential organ failure assessment (SOFA) score.
Results: The M group required a higher dose of noradrenaline compared with the V group to maintain MAP above the target level at 12 and 24 hours. There had been no significant variation in lactate levels along with SOFA scores between the two groups at earlier time points. However, at 24 hours, the M group had higher lactate levels and SOFA scores than the V group. The V group also showed improvements in urine output at 24 hours compared with the M group.
Conclusion: Early administration of vasopressin compared with MB was associated with a reduced dose of noradrenaline required for maintaining target MAP in patients presenting with septic shock.
Sahoo P, Kothari N, Goyal S, Sharma A, Bhatia PK. Comparison of norepinephrine and terlipressin vs. norepinephrine alone for management of septic shock: A randomized control study. Indian J Crit Care Med 2022;26(6):669–675. DOI: 10.5005/jp-journals-10071-24231.
Roy S, Kothari N, Sharma A, Goyal S, Sankanagoudar S, Bhatia PK, et al. Comparison of diagnostic accuracy of presepsin and procalcitonin for sepsis in critically ill patients: A prospective observational study. Indian J Crit Care Med 2023;27(4):289–293. DOI: 10.5005/jp-journals-10071-24439.
Mergoum AM, Rhone AR, Larson NJ, Dries DJ, Blondeau B, Rogers FB. A guide to the use of vasopressors and inotropes for patients in shock. J Intensive Care Med 2024:8850666241246230. DOI: 10.1177/08850666241246230.
Ruslan MA, Baharuddin KA, Noor NM, Yazid MB, Noh AYM, Rahman A. Norepinephrine in septic shock: A systematic review and meta-analysis. West J Emerg Med 2021;22(2):196–203. DOI: 10.5811/westjem.2020.10.47825.
Jozwiak M. Alternatives to norepinephrine in septic shock: Which agents and when? J Intensive Med 2022;2(4):223–232. DOI: 10.1016/j.jointm.2022.05.001.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021;47(11):1181–1247. DOI: 10.1007/s00134-021-06506-y.
Arias-Ortiz J, Vincent JL. Administration of methylene blue in septic shock: pros and cons. Crit Care 2024;28(1):46. DOI: 10.1186/s13054-024-04839-w.
Leone M, Einav S, Antonucci E, Depret F, Lakbar I, Martin-Loeches I, et al. Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pain Med 2023;42(3):101193. DOI: 10.1016/j.accpm.2023.101193.
Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: A narrative review. Adv Ther. 2020;37(9):3692–3706. DOI: 10.1007/s12325-020-01422-x.
ElAdawy M, Omran A. Methylene blue versus vasopressin in sepsis-induced vasoplegia. Ain-Shams Journal of Anaesthesiology. Ain-Shams J Anaesthesiol 2016;9(3):319. DOI: 10.4103/1687-7934.189091.
Luis-Silva F, Menegueti MG, Peres LM, Sepeda CDR, Jordani MC, Mestriner F, et al. Methylene blue therapy in addition to standard treatment for acute-phase septic shock: A pilot randomized controlled trial. Front Med (Lausanne) 2024;11:1431321. DOI: 10.3389/fmed.2024.1431321.
Ibarra-Estrada M, Kattan E, Aguilera-González P, Sandoval-Plascencia L, Rico-Jauregui U, Gómez-Partida CA, et al. Early adjunctive Methylene blue in patients with septic shock: A randomized controlled trial. Crit Care 2023;27(1):110. DOI: 10.1186/s13054-023-04397-7.
Ho BS, Lee YW, Lin YB. Impact of hourly serial SOFA score on signaling emerging sepsis. Inform Med Unlocked 2022;31(8):100999. DOI: 10.1016/j.imu.2022.100999.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001;27(8):1416–1421. DOI: 10.1007/s001340101014.
Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358(9):877–887. DOI: 10.1056/NEJMoa067373.
Jaiswal A, Kumar M, Silver E. Extended continuous infusion of methylene blue for refractory septic shock. Indian J Crit Care Med 2020;24(3):206–207. DOI: 10.5005/jp-journals-10071-23376.
Rajbanshi LK, Bajracharya A, Arjyal B, Devkota D. Can use of intravenous methylene blue improve the hemodynamics and outcome of the patients with refractory septic shock? an observational study. Indian J Crit Care Med 2023;27(9):669–674. DOI: 10.5005/jp-journals-10071-24535.
Huang X, Yan W, Chen Z, Qian Y. Effect of Methylene blue on outcomes in patients with distributive shock: A meta-analysis of randomised controlled trials. BMJ Open 2024;14(1):e080065. DOI: 10.1136/bmjopen-2023-080065.
Ballarin RS, Lazzarin T, Zornoff L, Azevedo PS, Pereira FWL, Tanni SE, et al. Methylene blue in sepsis and septic shock: A systematic review and meta-analysis. Front Med (Lausanne) 2024;11:1366062. DOI: 10.3389/fmed.2024.1366062.